权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Magnetohydrodynamic-based Laboratories on a Chip

基于磁流体动力学的芯片实验室

基本信息

批准号：
7125149
负责人：
Chamika Wansapura
金额：
$ 61.86万
依托单位：
VEGRANDIS, LLC
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-09-30 至 2009-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7125149
关键词：
Magnetohydrodynamic based Laboratories Chip

项目摘要

DESCRIPTION (provided by applicant): In this Phase II project, Vegrandis, LLC proposes to develop a magnetohydrodynamic (MHD) microfluidic based "sample-in, answer-out" bioassay chip for diagnosis of ovarian cancer. The proposed bioassay chip will use MHD microfluidics to pump the sample and reagents necessary to perform the assay and will have integrated micro-electrochemical detection of a panel of ovarian cancer biomarkers to provide quantitative results. A new approach to MHD microfluidics was demonstrated in Phase I to overcome previous limitations of bubble formation and short electrode life while retaining the key advantages of this approach to microfluidics. MHD microfluidics has a wide range of functionality, is compatible with a wide range of materials and solvents, and has several unique capabilities. One (1) key capability of MHD microfluidics which was demonstrated in Phase I is the ability to pump fluids along closed paths (e.g. a toroidal loop). This capability will be utilized in Phase II to realize the sealed bioassay chip with no external fluidic connections other than a self-sealing sample introduction port. An integrated, self-contained micro-electrochemical detection approach will be used to minimize false positives and false negatives and will provide quantitative results important for treatment monitoring. Together, the combination of MHD microfluidics and micro-electrochemical detection offer a unique platform for biomolecular analysis. For point-of-care diagnostic applications where minimum sample handling steps and maximum automation are typically essential features, the proposed system should excel. For the specific application proposed, the bioassay chip will use a newly developed panel of biomarkers from a subcontracted partner that can reliably detect all major ovarian tumor types in their early stage. A handheld analyzer instrument suitable for point-of-care use will also be developed. The proposed bioassay chip and analyzer will provide results in less than 30 minutes. This new ovarian cancer bioassay has the potential to become equivalent to the Pap test for cervical cancer as part of routine annual examinations that will provide for diagnosis of ovarian cancer while it is still in an early stage. Early intervention will not only dramatically increase the chances of surviving ovarian cancer, but will also allow application of less drastic treatment procedures and thereby improve the quality of life of the cancer survivor.

描述（由申请人提供）：在该II期项目中，Vegrandis，LLC提出开发一种基于磁流体动力学（MHD）微流体的“进样，应答”生物测定芯片，用于诊断卵巢癌。拟议的生物测定芯片将使用MHD微流体泵送进行测定所需的样品和试剂，并将集成一组卵巢癌生物标志物的微电化学检测，以提供定量结果。在第一阶段中展示了一种新的MHD微流体方法，以克服以前的气泡形成和短电极寿命的限制，同时保留这种微流体方法的关键优势。MHD微流体具有广泛的功能，与多种材料和溶剂兼容，并具有多种独特的功能。在第一阶段中证明的MHD微流体的一个（1）关键能力是沿着沿着闭合路径（例如环形回路）泵送流体的能力。这种能力将在第II阶段中利用，以实现除了自密封样品引入端口之外没有外部流体连接的密封生物测定芯片。将使用集成的、独立的微电化学检测方法来最大限度地减少假阳性和假阴性，并将提供对治疗监测重要的定量结果。MHD微流体和微电化学检测的结合为生物分子分析提供了一个独特的平台。对于床旁诊断应用，最少的样品处理步骤和最大的自动化是典型的基本特征，所提出的系统应优于。对于提出的具体应用，生物测定芯片将使用来自分包合作伙伴的新开发的生物标志物组，可以可靠地检测早期所有主要卵巢肿瘤类型。还将开发一种适用于现场护理的手持式分析仪。拟议的生物测定芯片和分析仪将在30分钟内提供结果。这种新的卵巢癌生物测定法有可能与宫颈癌的巴氏试验相当，作为常规年度检查的一部分，在卵巢癌仍处于早期阶段时提供卵巢癌的诊断。早期干预不仅会大大增加卵巢癌的生存机会，而且还可以应用不太激烈的治疗程序，从而提高癌症幸存者的生活质量。